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INTRODUCTION
Probiotics are non-pathogenic microorganisms that confer a 
health benefit on the host
1 by improving the balance of the in-
testinal microflora and possibly by augmenting host defenses. 
Several studies have characterized the ability of probiotic strains 
to alter cytokine production in the gut and associated lymphoid 
tissue, demonstrating immunomodulatory effects on some al-
lergic diseases.
2-4 Successful probiotic treatments in animal mod-
els of asthma have recently been described,
5,6 and we have re-
ported that oral Lactobacillus rhamnosus (Lcr35) treatment pri-
or to allergic sensitization can attenuate airway inflammation 
and hyperreactivity in a mouse model of allergic airway inflam-
mation.
7 However, the beneficial effects of probiotics on the de-
velopment of allergic asthma and allergic rhinitis in human clin-
ical trials remains controversial.
8,9 Despite conflicting results, it 
is generally thought that the immunomodulatory effect of pro-
biotics on allergic diseases is a promising area of research.
10,11
A number of studies have suggested that the immunosup-
pressive cytokines interleukin-10 (IL-10) and transforming 
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growth factor (TGF)-β along with regulatory T (Treg) cells are 
the main mechanisms by which probiotics suppress allergic in-
flammation.
2,5,12 Nevertheless, there have been few mechanistic 
studies of probiotic activity in allergic disease. In the present 
study, we aimed to confirm the involvement of Treg cells in the 
protective effect of Lcr35 in a mouse model of allergic asthma.
MATERIALS AND METHODS
Mice
Female BALB/c mice weighing 20-25 g (4 weeks old) were 
purchased from Orient Bio (Orient Bio Inc., Seongnam, Korea) 
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Purpose:  Probiotic bacteria can induce immune regulation or immune tolerance in allergic diseases. The underlying mechanisms have been recent-
ly investigated, but are still unclear. The aim of this study was to evaluate the protective effects of the probiotic Lactobacillus rhamnosus (Lcr35) in a 
mouse model of asthma and to identify its mechanism of action.  Methods:  Lcr35 was administered daily by the oral route at a dosage of 1×10
9 
CFU/mouse in BALB/c mice for 7 days before the first sensitization. Clinical parameters and regulatory T (Treg) cells were examined. The role of 
CD4
+CD25
+Foxp3
+ Treg cells was analyzed using a Treg cell-depleting anti-CD25 monoclonal antibody (mAb).  Results:  Airway hyperresponsive-
ness, total IgE production, pulmonary eosinophilic inflammation, and splenic lymphocyte proliferation were suppressed after Lcr35 treatment. Th1 
(IFN-γ) and Th2 (IL-4, IL-5, and IL-13) cytokines in the serum were suppressed, and the percentage of CD4
+CD25
+Foxp3
+ Treg cells in the spleen was 
significantly increased in the Lcr35 treatment group. Anti-CD25 mAb administration abolished the protective effects of Lcr35, indicating that CD4
+
CD25
+Foxp3
+ Treg cells are essential in mediating the activity of Lcr35.  Conclusions:  Oral administration of Lcr35 attenuated the features of aller-
gic asthma in a mouse model and induced immune regulation by a CD4
+CD25
+Foxp3
+ Treg cell-mediated mechanism.
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and treated in accordance with the guidelines of the Institu-
tional Animal Care and Use Committee (IACUC) at Asan Medi-
cal Center and Ulsan University College of Medicine.
Probiotic preparation
The Lcr35 used in this study was obtained from the Lyocen-
tre
® laboratory (Aurillac, France) and was cultured in sterile 
Lactobacillus MRS broth (Difco, Sparks, MD, USA) at 37°C for 
24 hours. After cultivation, cells were collected by centrifuga-
tion at 5,000×g for 10 minutes, washed twice with phosphate 
buffered saline (PBS), and lyophilized. The lyophilized powder 
was reconstituted with sterile saline before use.
Establishment of allergic asthma and probiotic treatment
Six-week-old female BALB/c mice (N=7 per group) were sen-
sitized by intraperitoneal (i.p.) administration of an ovalbumin 
(OVA; 10 µg, grade V; Sigma Chemical Co., St. Louis, MO, USA) 
and alum (2.25 mg; Imject
®, Pierce, Rockford, IL, USA) mixture. 
One week after the first sensitization, the mixture was adminis-
tered a second time. Seven days later, the mice inhaled 1% OVA 
via an ultrasonic sprayer (Nescosonic UN-511; Alfresa, Osaka, 
Japan) for 30 minutes daily for three successive days (OVA chal-
lenge). The mice received Lcr35 (1×10
9 colony-forming units/
600 μL/mouse/day) orally from one week before primary sensi-
tization to the endpoint of the study. Negative controls received 
only saline instead of OVA at both sensitizations and airway 
challenge. Positive controls received nothing more after OVA 
sensitization.
Clinical evaluations in vivo
Airway hyperresponsiveness (AHR) in response to inhaled 
methacholine (MeCh; Sigma Chemical Co.), administered 24 
hours after OVA challenge, was measured in conscious, unre-
strained mice using a barometric whole-body plethysmograph 
(Buxco; EMKA Technologies, Paris, France). Briefly, mice were 
placed in a whole-body chamber, and basal readings were ob-
tained for 3 minutes and averaged. Aerosolized saline followed 
by 5-50 mg/mL MeCh were inhaled for 3 minutes after each 
MeCh inhalation.
Treg cells were depleted using anti-CD25 monoclonal anti-
body (mAb). Briefly, mice received 250 μg of rat anti-mouse 
CD25 mAb (clone PC61; eBioscience, San Diego, CA, USA) i.p. 
in 400 μL of normal saline one day before 1% OVA challenge. 
Control mice were injected with 250 μg of rat IgG1 (Sigma 
Chemical Co.).
Bronchoalveolar lavage (BAL) fluid analysis
After measurement of AHR, the mice were anesthetized by i.p. 
administration of ketamine-xylazine, and the trachea was im-
mediately exposed. The airways were lavaged through a trache-
al cannula, two times with 1-mL aliquots of pyrogen-free saline 
warmed to 37°C. The recovered lavage fluid was pooled, and 
the cells were collected by centrifugation (5,000 rpm, 4°C, 5 
minutes) and resuspended in 100 mL of cold PBS. The cells 
were stained with trypan blue to determine viability, and total 
nucleated cells were counted using a hemocytometer.
For differential BAL cell counts, cytospin preparations were 
made and stained with Diff-Quik (Sysmex, Takatsukadai, Ja-
pan). After the samples were coded, all cytospin preparations 
were evaluated by one observer using an oil immersion micro-
scope (magnification, ×1,000). At least 200 cells were counted 
per preparation, and the absolute number of each cell type was 
calculated.
Serum Ig analysis
Serum was obtained from blood taken during exsanguination 
of the mice after airway measurement, and 100 μL (1/10 dilu-
tion in carbonate-bicarbonate buffer) were added to each well 
of a 96-well plate. An IgE-specific enzyme linked immunosor-
bent assay (ELISA) was used to quantitate total IgE in the se-
rum, using matching antibody pairs (eBioscience) according to 
the manufacturer’s instructions. For the ELISA, 96-well plates 
were first coated overnight with rat anti-mouse IgE (10 μL in 
100 μL of PBS; PharMingen, San Diego, CA, USA), rat anti-
mouse IgG1 (20 μg in 100 μL of PBS; PharMingen), or rat anti-
mouse IgG2a (20 μg in 100 μL of PBS; PharMingen). The remain-
ing binding sites were blocked, and the plates were incubated 
with 100 μL of diluted serum (1:5 for IgE, 1:10 for IgG1 or IgG2a). 
After the plate was washed, each of the following was sequen-
tially added, incubated, and removed by washing: OVA (1 μg/
100 μL), peroxidase-labeled rabbit anti-OVA Ig (240 ng/100 μL, 
PharMingen), and 3,3,5,5-tetramethylbenzidine solution (Sig-
ma Chemical Co.). The optical density was measured at 450 
nm, and the Ig level was determined relative to that of a refer-
ence pool of serum from OVA-sensitized BALB/c mice (assigned 
a value of 100 experimental units/mL). Determinations were 
performed in duplicate.
Cytokine assays
Commercial preparations of paired antibodies and protein 
standards for measurements of mouse IL-4, IL-5, IL-13, and 
IFN-γ (eBioscience) in sera were used to develop ELISAs ac-
cording to the manufacturer’s instructions. Determinations 
were performed in duplicate.
Lymphocyte proliferation assay
After BAL, the mouse spleen was resected. Mouse splenocytes 
were separated on a Histopaque (Sigma Chemical Co.) gradient, 
and the collected cells were washed with PBS. RBCs were lysed 
by gently mixing the cells with 3.6 mL of 0.24% NaCl for 20 sec-
onds, followed by the quick addition of 0.3 mL of 8.7% NaCl 
and further dilution with PBS. The pellet was suspended in Is-
cove’s Modified Dulbecco’s Medium (IMDM), and stored over-
night at 4°C. The next morning, the cells were centrifuged at Jang et al.
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4°C, suspended in cold PBS, stained with trypan blue, and 
counted using a hemocytometer.
Splenic T cells were cultured in IMDM supplemented with 25 
mM HEPES, 10% (v/v) heat inactivated fetal bovine serum (FBS), 
60 mg/L (100 U/mL) penicillin, 100 mg/L streptomycin, and 
0.29 g/L L-glutamine. Splenic T cells were adjusted to 1×10
5 
cells/200 μL/well, transferred to 96-well plates, and incubated 
at 37°C in a humidified 5% CO2 incubator for 72 hours. The cells 
were stimulated with OVA treatment (100 μg/mL) for 72 hours. 
At 12 hours before the end of the incubation, 1 μCi of [
3H]-thy-
midine was added to each well. The cells were harvested onto a 
glass microfiber filter (Simport, Beloeil, Canada), and radioac-
tivity was measured in a liquid scintillation counter. The incor-
poration during the last 12 hours of culture (counts per minute) 
was used as an index of proliferation. All cultures were tested in 
triplicate.
Flow cytometry
Mouse Treg cells were collected from the spleen and analyzed 
for CD4
+CD25
+Foxp3
+ expression using a mouse Treg cell stain-
ing kit containing FITC-labeled anti-CD4, APC-labeled anti-
CD25, and PE-labeled anti-Foxp3 (eBioscience) according to 
the manufacturer’s instructions. Briefly, prepared cells (1×10
6) 
were washed by centrifugation with cold PBS, resuspended in 1 
mL of fixation/permeabilization solution, and incubated in the 
dark at 4°C for 30-60 minutes. The cells were washed once with 
2 mL of permeabilization buffer, collected by centrifugation, re-
suspended in 20 mL of blocking agent with 2% (2 mL) normal 
rat serum in permeabilization buffer, and incubated at 4°C for 
15 minutes. Next, 20 mL of fluorochrome-conjugated antibody 
or isotype control in permeabilization buffer were added, fol-
lowed by incubation in the dark at 4°C for 30 minutes. Finally, 
the cells were washed with 2 mL of permeabilization buffer, re-
suspended in flow cytometry buffer (PBS with 2% FBS), and 
analyzed by flow cytometry using a FACSCalibur with CellQuest 
software (BD Biosciences, Mountain View, CA, USA). Determi-
nations were performed in duplicate.
Lung histopathology
For the histological evaluation of lung tissue, the left lung of 
each mouse was embedded in paraffin, sectioned to a thickness 
of 5 μm, and stained with hematoxylin and eosin (H&E) to as-
sess eosinophilic infiltration. Inflammation was scored by two 
independent, blinded investigators. The degree of peribronchi-
al and perivascular inflammation was evaluated on a subjec-
tive scale of 0-3, as described elsewhere.
13 Cellular infiltration in 
five randomly selected fields was assessed under a Zeiss Axio-
phot microscope (magnification, ×100; Carl Zeiss, Inc., Thorn-
wood, NY, USA).
Statistical analysis
We analyzed the association between groups and positive 
controls using the Mann-Whitney test. Data are expressed as 
means±standard error. All statistical analyses were performed 
using SPSS ver. 18.0 for Windows (SPSS Inc., Chicago, IL, USA). 
A P value<0.05 indicated significance.
RESULTS
Effect of Lcr35 treatment on maximal Penh and airway 
eosinophilia
Lcr35 administration to allergic mice significantly suppressed 
AHR, to the level of the negative control group at the maximum 
MeCh dose (negative control: 4.72±2.19; Lcr35-treated: 4.75±
1.56; positive control: 9.00±2.87; P<0.01) (Fig. 1A).
Lcr35-treated mice exhibited a significant suppression of BAL 
fluid total cell count compared with positive controls (Lcr35-
treated: 4.77×10
5 cells/mL; positive control: 8.29×10
5 cells/mL;
 P<0.05). Oral administration of Lcr35 significantly reduced the 
number of eosinophils in BAL fluid compared with positive 
controls (Lcr35-treated: 3.79±0.29%; positive control: 13.60±
3.00%; P<0.05) (Fig. 1B).
Lung inflammation after OVA inhalation was significantly re-
duced by oral administration of Lcr35 (Lcr35-treated: 2.16±
0.55; positive control: 0.92±0.52; P<0.05) (Fig. 1C). Examina-
tion of the lung tissue of positive control mice revealed peri-
bronchial and perivascular cellular infiltrates; Lcr35 treatment 
produced a marked decrease in both cellular infiltration and 
inflammatory changes, as determined by histopathology (Fig. 
1D). Thus, Lcr35 treatment inhibited allergen-induced pulmo-
nary inflammation, including the influx of eosinophils.
Mechanism of the effect of Lcr35 on allergic responses
The administration of Lcr35 significantly reduced the total IgE 
level compared with that of the positive control, but had no sig-
Table.  Systemic immune responses and cytokine levels of each group
Parameter Group Negative Lcr35 Positive
Systemic immunoglobulins
Total IgE (pg/mL) 4,041±229.3* 5,777±387.7
† 7,427±381.1
OVA-specific IgE 
(ng/mL)
4,232±170.0* 6,370±423.5 7,666±391.2
OVA-specific IgG1 
(μg/mL)
3,978±457.7* 7,201±518.3 7,813±553.8
OVA-specific IgG2a 
(μg/mL)
36.48±13.25* 68.74±3.11 75.90±3.83
Serum cytokines
IL-4 (pg/mL) 3.96±0.28* 4.68±0.52
† 7.68±0.74
IL-5 (pg/mL) 42.60±5.67* 84.40±6.49
† 151.0±14.29
IL-13 (pg/mL) 441.4±29.6* 957.5±35.6
† 1,377.0±112.1
IFN-γ (pg/mL) 87.76±12.43
† 176.00±5.30 191.60±21.19
*P<0.01; 
†P<0.05 (compared with the positive control).
Lcr35, Lactobacillus rhamnosus; OVA, ovalbumin.Mechanism of Probiotics on Asthma in a Mouse Model
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nificant effect on OVA-specific IgE, IgG1, or IgG2a (Table). Se-
rum IL-4, -5, and -13 levels were significantly suppressed by 
orally administered Lcr35. The IFN-γ level was also decreased 
in Lcr35-treated mice, but the difference was not significant 
(Table). These results suggest that Lcr35 treatment suppresses 
Th2-dependent cytokines. OVA-induced cell proliferation was 
significantly lower in Lcr35-treated mice than in positive con-
trol mice (Fig. 2). Thus, Lcr35 effectively inhibited the OVA-spe-
cific splenic T cell response.
Lcr35 treatment led to a significant increase in CD4
+CD25
+
Foxp3
+ Treg cells, compared with the percentage in positive 
control mice (Lcr35-treated: 17.60±0.49%; positive control: 
15.20±0.44%; P<0.05) (Fig. 3B). This suggests that Lcr35-in-
duced attenuation of allergic responses in the mouse model of 
asthma is associated with an increased CD4
+CD25
+Foxp3
+ Treg 
cell population. To confirm the involvement of CD4
+CD25
+ 
Foxp3
+ Treg cells, Treg cell depletion was achieved by anti-
CD25 mAb treatment. Anti-CD25 mAb treatment before OVA 
challenge significantly increased AHR at the maximum MeCh 
dose, compared with AHR in Lcr35-treated mice (anti-CD25-
treated: 8.16±1.63; Lcr35-treated: 3.30±0.57; P<0.05) (Fig. 4A). 
Fig. 2.  Effect of oral Lcr35 treatment on the suppression of OVA-specific splen-
ic T cell proliferation in a mouse model. *P<0.05 and **P<0.01. Negative con-
trol: Saline (i.p.)/saline challenge by inhalation. Lcr35-treated: OVA (i.p.)/OVA 
challenge by inhalation+Lcr35 (oral administration). Positive control: OVA (i.p.)/
OVA challenge by inhalation.
Lcr35, Lactobacillus rhamnosus; OVA, ovalbumin; i.p., intraperitoneal.
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Fig. 1.  Effect of oral Lcr35 treatment on allergic asthma in a mouse model. (A) Airway hyperresponsiveness; (B) Eosinophil proportion in bronchoalveolar lavage flu-
id; (C) Peribronchial and perivascular lung inflammation score; (D) Lung pathology. *P<0.05 and **P<0.01. Negative control: Saline (i.p.)/saline challenge by inhala-
tion. Lcr35-treated: OVA (i.p.)/OVA challenge by inhalation+Lcr35 (oral administration). Positive control: OVA (i.p.)/OVA challenge by inhalation.
Lcr35, Lactobacillus rhamnosus; i.p., intraperitoneal; OVA, ovalbumin.
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Fig. 3.  Effect of oral Lcr35 treatment on the CD4
+CD25
+Foxp3
+ Treg population 
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+Foxp3
+ Treg cells among total splenic T cells after Lcr35 treatment in 
comparison with cells obtained from the positive control (Group 3). *P<0.05. 
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The isotype control rat IgG1 had no effect on AHR (data not 
shown). Anti-CD25 treatment also significantly decreased the 
population of CD4
+CD25
+Foxp3
+ Treg cells in Lcr35-treated 
mice (anti-CD25 treated: 1.00±0.08%; Lcr35-treated: 15.53±
0.10%; P<0.05) (Fig. 4B). These results suggest that CD4
+CD25
+
Foxp3
+ Treg cells are involved in the suppression of AHR medi-
ated by oral administration of Lcr35.
The pulmonary inflammation score was also significantly 
higher in anti-CD25 mAb-treated Lcr35 mice compared with 
Lcr35-treated mice that did not receive anti-CD25 mAb (anti-
CD25 treated: 2.28±0.19; Lcr35-treated 1.32±0.20; P<0.01) 
(Fig. 4C). The histopathology revealed enhanced eosinophilic 
inflammation in the lungs of anti-CD25-treated Lcr35 mice 
compared with anti-CD25 mAb-non-treated Lcr35 mice (Fig. 
4D). The data indicate that administration of anti-CD25 mAb 
reverses the effect of oral Lcr35 treatment on lung inflamma-
tion and that Treg cells mediate the effect of Lcr35.
DISCUSSION
This study examined the effect of oral Lcr35 on allergic asth-
ma in a mouse model. The major finding was that Lcr35 sup-
presses allergic parameters, including AHR, airway inflamma-
tion, and total IgE, by regulating the activity of CD4
+CD25
+Foxp3
+ 
Treg cells. In addition, these effects were reversed by adminis-
tration of anti-CD25 mAb.
The effect of probiotics on Th1 cytokines is controversial, as 
probiotics have been shown to promote, inhibit, and have no 
effect on Th1 cytokine production.
14-16 In our study, serum lev-
els of Th2 cytokines were reduced by oral Lcr35 treatment, 
whereas Th1 cytokine levels were not significantly reduced. We 
did not determine cytokine levels in target organs or BAL fluid; 
this is a limitation of this study.
To test our hypothesis, CD4
+CD25
+Foxp3
+ Treg cell numbers 
in the spleen were determined. Treg cell numbers were signifi-
cantly higher after Lcr35 treatment. Exacerbation readouts of 
asthma after Treg depletion demonstrated the importance of 
Treg cells in the protective effect of Lcr35. This suggests that 
Treg cells may be involved in the protection conferred by oral 
Lcr35 in the mouse model of asthma. However, other potential 
mechanisms such as immunosuppressive cytokines (IL-10 and 
TGF-β) were not examined. To our knowledge, this is the first 
study to identify the mechanism of action of probiotics using 
depletion of CD4
+CD25
+Foxp3
+ Treg cells in a mouse model of 
asthma.
Some reports have suggested that the involvement of thymus-
derived natural Treg cells expressing Foxp3 and CD25 in toler-
ance to allergens is unlikely, and the expression of Foxp3 and 
CD25 on Treg cells remains controversial.
10 Further studies are 
needed to confirm the mechanism underlying the protective 
effect of Lcr35.
Many studies have attempted to identify the mechanism of 
action of probiotics in allergic diseases.
2-4 Several have implicat-
ed Treg cells in the activity of probiotics,
2,17 but these studies did 
not investigate changes in the inflammatory response after 
Treg cell depletion. Our study is important in that it confirms 
previous hypotheses that Treg cells contribute to the protective 
effect of probiotics.
Oral administration of Lcr35 completely blocked OVA-specific 
proliferation of splenic T cells in the present study. This sug-
gests that Lcr35 regulates the systemic immune response in 
OVA-sensitized and -challenged mice. Oral administration of 
probiotics induces regulatory dendritic cells, which in turn pro-
mote the generation of CD4
+Foxp3
+ Treg cells in mesenteric 
lymph nodes.
2 Dendritic cells can directly present antigens 
from commensal bacteria to mesenteric lymph nodes and in-
teract with T and B cells to maintain a non-inflammatory im-
mune response.
3,4
In contrast to the massive eosinophilic infiltration in the peri-
bronchial and perivascular areas of positive control mice, ani-
mals treated with Lcr35 showed significantly less eosinophilic 
inflammation. This was coincident with decreased production 
of the Th2 cell-derived cytokines IL-4, IL-5, and IL-13 in the 
Lcr35 treatment group.
There is strong evidence implicating CD4
+CD25
+ Treg cells in 
controlling allergic diseases. For example, the transfer of CD4
+
CD25
+ Treg cells to sensitized mice reduced AHR, eosinophilic 
inflammation, and Th2 cytokine induction in the lung, in an IL-
10-dependent manner.
18,19 It is widely believed that administra-
tion of an anti-CD25 mAb results in the rapid and efficient de-
pletion of CD4
+CD25
+ Treg cells, and this has been confirmed 
by secondary staining with a mAb directed against a different 
CD25 epitope.
20,21 Previous studies have shown that the num-
ber of CD4
+CD25
+ Treg cells was significantly decreased within 
3 days of anti-CD25 mAb treatment in vivo, but had recovered 
to normal levels by day 10.
22,23 Therefore, in this study, we ad-
ministered anti-CD25 mAb one day before OVA challenge. As 
expected, the anti-allergic effects of Lcr35 disappeared, and the 
CD4
+CD25
+Foxp3
+ Treg cell population was significantly re-
duced. This demonstrates that the beneficial effect of Lcr35 on 
allergic asthma in the mice was mediated by CD4
+CD25
+Foxp3
+ 
Treg cells.
In conclusion, we demonstrated that the suppression of aller-
gic responses and immunomodulation by the probiotic Lcr35 
in a mouse model of asthma was mediated by the activity of 
CD4
+CD25
+Foxp3
+ Treg cells.
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